首页> Cancer chemotherapy and pharmacology.> EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

导出原文传递

翻译打印收藏纠错

第一作者： Huang, Thomas

作者： Huang, Thomas ^[1] ; Engelmann, Brigitte J. ^[2] ; Morgan, Rachael M. ; Absher, Kimberly J. ; Kolesar, Jill M. ; Villano, John L.

作者单位： Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA ^[1] Univ Kentucky, Dept Med, Lexington, KY 40506 USA ^[2]

关键词 Squamous cell lung cancer EML4-ALK translocation Crizotinib Alectinib Smoking Anti-ALK inhibitor treatment

发布时间 2019-04-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer chemotherapy and pharmacology.

2018年81卷5期

965-968页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Cancer chemotherapy and pharmacology.

2018年81卷5期

965-968页

检索历史清除

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Cancer chemotherapy and pharmacology.

相似文献

同项目论文

Cancer chemotherapy and pharmacology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

EML4-ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

Cancer chemotherapy and pharmacology.

相似文献

同项目论文

Cancer chemotherapy and pharmacology.

相关期刊

检索历史清除